JP2024539581A5 - - Google Patents
Info
- Publication number
- JP2024539581A5 JP2024539581A5 JP2024519605A JP2024519605A JP2024539581A5 JP 2024539581 A5 JP2024539581 A5 JP 2024539581A5 JP 2024519605 A JP2024519605 A JP 2024519605A JP 2024519605 A JP2024519605 A JP 2024519605A JP 2024539581 A5 JP2024539581 A5 JP 2024539581A5
- Authority
- JP
- Japan
- Prior art keywords
- phase
- composition according
- active agent
- bladder
- plga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256583P | 2021-10-17 | 2021-10-17 | |
| US63/256,583 | 2021-10-17 | ||
| PCT/IL2022/051090 WO2023062638A1 (en) | 2021-10-17 | 2022-10-14 | Compositions and methods for drug instillation into the urinary bladder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539581A JP2024539581A (ja) | 2024-10-29 |
| JP2024539581A5 true JP2024539581A5 (enExample) | 2025-08-08 |
Family
ID=85987609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519605A Pending JP2024539581A (ja) | 2021-10-17 | 2022-10-14 | 膀胱への薬物注入のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250228767A1 (enExample) |
| EP (1) | EP4415821A4 (enExample) |
| JP (1) | JP2024539581A (enExample) |
| KR (1) | KR20240089461A (enExample) |
| CN (1) | CN118234483A (enExample) |
| AU (1) | AU2022365519A1 (enExample) |
| CA (1) | CA3235477A1 (enExample) |
| WO (1) | WO2023062638A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025180652A1 (en) * | 2024-02-28 | 2025-09-04 | Farco-Pharma Gmbh | Drug delivery systems for instillation in the urinary bladder comprising active pharmaceutical ingredients |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| WO2010088924A1 (en) * | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| EP2525777B1 (en) * | 2010-01-20 | 2019-05-29 | UroGen Pharma Ltd. | Material and method for treating internal cavities |
| US8754564B2 (en) * | 2010-05-27 | 2014-06-17 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
| US9757497B2 (en) * | 2011-05-20 | 2017-09-12 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
| EP2734187B1 (en) * | 2011-07-20 | 2018-09-05 | UroGen Pharma Ltd. | Materials and method for treating internal body cavities |
| DK2836200T3 (da) * | 2012-04-08 | 2020-09-21 | Urogen Pharma Ltd | Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium |
| US9801854B1 (en) * | 2014-01-17 | 2017-10-31 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| US20190209502A1 (en) * | 2016-09-12 | 2019-07-11 | Evofem, Inc. | Combination gel for sexually transmitted infections |
| US20220211615A1 (en) * | 2019-04-30 | 2022-07-07 | Trigone Pharma Ltd. | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments |
-
2022
- 2022-10-14 WO PCT/IL2022/051090 patent/WO2023062638A1/en not_active Ceased
- 2022-10-14 CN CN202280070028.5A patent/CN118234483A/zh active Pending
- 2022-10-14 CA CA3235477A patent/CA3235477A1/en active Pending
- 2022-10-14 US US18/701,630 patent/US20250228767A1/en active Pending
- 2022-10-14 EP EP22880543.8A patent/EP4415821A4/en active Pending
- 2022-10-14 KR KR1020247015333A patent/KR20240089461A/ko active Pending
- 2022-10-14 JP JP2024519605A patent/JP2024539581A/ja active Pending
- 2022-10-14 AU AU2022365519A patent/AU2022365519A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2273017C (fr) | Dispositif d'administration locale de formulations solides ou semi-solides, formulations retard pour administration parenterale et procede de preparation | |
| Martín del Valle et al. | Drug delivery technologies: the way forward in the new decade | |
| JP7323608B2 (ja) | スマート放出のための非注射用ヒドロゲル製剤 | |
| US12171747B2 (en) | Material and method for treating cancer | |
| CN102933234A (zh) | 可注射长效组合物的制备方法 | |
| PT950403E (pt) | Emulsões para sistemas de libertação in situ | |
| US11793762B2 (en) | Composition and method for reducing joint pain associated with hemarthrosis and hemophilic arthropathy | |
| Bode et al. | In-situ forming PLGA implants: How additives affect swelling and drug release | |
| Singh et al. | Chitosan nanoparticles: a versatile frontier in drug delivery and wound healing across multiple routes | |
| CN107073112A (zh) | 用于在患有脊髓损伤的对象中抑制炎症的组合物及其使用方法 | |
| RU2394558C2 (ru) | Формирующийся in situ имплантат для животных | |
| CN105101962A (zh) | 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放 | |
| US20250228767A1 (en) | Compositions and methods for drug instillation into the urinary bladder | |
| KR20250091219A (ko) | 위장관의 염증을 치료 및 예방하기 위한 장시간 작용하는 플루티카손 프로피오네이트 주사용 현탁액의 사용 | |
| Enggi et al. | In situ gel forming formulations | |
| CN113081952A (zh) | 一种含有恩替卡韦的长效注射凝胶 | |
| HK40065558A (en) | Non-injectable hydrogel formulations for smart release | |
| HK40093454A (zh) | 长效原位成型/胶凝组合物 |